What diseases does Betaserc treat?

Vestibular dizziness with nausea and vomiting is not a rare disease today. Besides conventional drugs, doctors often prescribe Betaserc to treat this condition.

Betaserc contains the active ingredient Betahistine Dihydrochloride, is available in the form of tablets, round, white, biconvex, oblique and notched on one side. The notched side of the Betaserc tablet has the number 267 engraved on one notched side. Due to the notch, Betaserc tablets can be broken in half to divide into 2 uses. In addition to the main ingredient betahistine dihydrochloride, Betaserc also includes a number of excipients such as microcrystalline cellulose, mannitol, citric acid monohydrate, colloidal anhydrous silica and talc.

Prescription Betaserc is a product against vertigo. Currently, scientists only partially understand the mechanism of action of the active ingredient Betahistine. Several hypotheses have been confirmed through the results of studies performed on animals and data collected in humans, specifically as follows:
Betahistine has the ability to act on the Histamine system: This active substance has an effect on the Histamine system. antagonism at both histamine H1 and H3 receptors in nerve tissues, H2 receptors alone are insignificant. Therefore, Betahistine can stimulate increased metabolism and increase histamine secretion by blocking presynaptic H3 receptors, combined with H3 receptor upregulation; Betahistine stimulates increased circulation to the cochlea and the whole brain: Several animal experiments have shown that betahistine has the ability to improve blood circulation in the vascular striatum of the inner ear. Besides, Betahistine also shows the ability to increase cerebral blood circulation in humans; Betahistine helps to regulate vestibular function: The active ingredient in Betaserc has been shown to promote recovery of the vestibular system after unilateral neurosurgery in animals because of its ability to support central vestibular correction. In humans, Betahistine has also been shown to reduce the recovery time after neurectomy; Betahistine alters nerve impulse conduction in the vestibular nucleus: Specifically, it inhibits nerve impulse conduction on the dendrites of neurons in the lateral and mid-vestibular nuclei. Research results to date demonstrate the therapeutic benefits of Betahistine on the vestibular system. The effectiveness of Betaserc has also been demonstrated in studies in people with vertigo and Ménière's disease through its ability to improve the condition and reduce the frequency of vertigo episodes.

Indications of Betaserc include:
Ménière's syndrome through the relief of the following main symptoms: Dizziness: Including dizziness, dizziness accompanied by nausea, vomiting; Reduced hearing or hearing loss; Tinnitus: The ability to perceive sounds inside the ear does not correspond to sounds from outside; Betaserc is indicated for the treatment of symptoms of vestibular vertigo, including a feeling of dizziness, often accompanied by nausea and vomiting, which occurs even when the patient is standing still.

Patients need to use Betaserc drug according to the doctor's prescription, if there are any questions, they should discuss with the doctor or pharmacist. The specific dosage of Betaserc is as follows:
Adults: The starting dose is 8 - 16mg, maximum 24 - 48mg/day, divided into 3 oral doses per day. Your doctor will adjust the dose according to the patient's response, usually dizziness symptoms can improve after 2 weeks and sometimes only achieve the best treatment results after a few months of using Betaserc. Some patients are indicated to be treated with Betaserc at the very beginning of the disease with the aim of limiting disease progression or preventing hearing loss in Ménière's syndrome; Children: Betaserc is not recommended for use in people under 18 years of age because there are insufficient data on safety and efficacy; Elderly: Data in this population from clinical studies are limited but still suggest that no dose adjustment of Betaserc is necessary; Renal and/or hepatic impairment: There are no specific clinical studies in this patient population, but empirically dose adjustment may not be necessary. In some cases, Betaserc should not be used, including:
History of allergy (hypersensitivity) to Betahistine or any of the excipients of Betaserc; Adrenal tumors (such as pheochromocytoma).

Patients with a history of bronchial asthma or stomach ulcers (gastrointestinal ulcers) before using Betaserc should inform their doctor to have a plan for careful monitoring.
Some undesirable side effects of Betaserc drug: The following effects were studied in terms of frequency when using Betaserc in patients and in placebo-controlled patients: common (common from 1 to 10 cases). cases in 100 treated patients):
Gastrointestinal disorders: Nausea, vomiting, dyspepsia or stomach pain; Nervous disorders : Common is headache ; Immune system disorders: Allergic conditions, including severe and possibly causing difficulty breathing, swelling of the face and neck, dizziness; Skin and subcutaneous adipose tissue abnormalities: Very rarely, skin hypersensitivity reactions, sudden onset of swelling (neuroedema) of the neck or limbs, urticaria, rash and itch.

Currently, the drug interactions of Betaserc have not been studied in vivo. The available data are based on the results of laboratory studies (in vitro) and do not show inhibition of the cytochrome P450 enzyme system in vivo.
If you are taking Monoamine-oxidase (MAO) inhibitors and medications for depression or Parkinson's, you should tell your doctor.
Betahistine has a similar structure to Histamine, so the interaction between Betaserc and antihistamines can affect the effectiveness of both. Therefore, patients should discuss with their doctor if they are being treated with active ingredients. Antihistamines before taking Betaserc.

Storage: Do not store Betaserc at temperatures above 30°C; Effects on ability to drive: Betahistine is indicated for the treatment of Meniere's syndrome and vestibular vertigo. Both of these conditions have the potential to negatively affect the ability to drive and use machines. However, in clinical studies investigating the effects of Betaserc on the ability to drive and use machines, it was found to have no or negligible influence; Pregnant women should consult their doctor or pharmacist before using Betaserc. Currently, data regarding the use of Betaserc in pregnancy are incomplete. Animal studies have not demonstrated the full effects of betahistine during pregnancy, effects on embryonic development, labor, and neonatal development. Therefore, it is not recommended to use Betaserc during pregnancy unless absolutely necessary; Lactation: It is not known whether Betaserc is excreted in human milk, including from animal studies. Betaserc should not be used during breastfeeding. For more information, consult your physician about the importance of the drug, its potential benefits and risks to a nursing infant; Overdose: There are very few cases of overdose with Betaserc. Some may experience mild to moderate symptoms such as nausea, drowsiness and abdominal pain when taking up to 640mg of betahistine. More serious risks (eg, convulsions, cardiopulmonary complications) can occur with intentional overdose of both Betaserc and many other drugs. Currently, there is no specific antidote to betahistine, so the treatment of overdose cases is mainly symptomatic measures.